Vascular calcification is a crucial risk factor that affects the incidence and mortality of cardiovascular disease in chronic kidney disease patients.Modern medicine relies on calcium-phosphorus binding agents,calcium...Vascular calcification is a crucial risk factor that affects the incidence and mortality of cardiovascular disease in chronic kidney disease patients.Modern medicine relies on calcium-phosphorus binding agents,calcium mimetics,active vitamin D,and hemodialysis to prevent and treat vascular calcification,however,their efficacy is unsatisfactory and adverse reactions often occur.Medical plant therapy can act as an integrative regulator in patients with chronic kidney disease-associated vascular calcification,which can significantly improve patients’symptoms,but its specific mechanism has not been fully elucidated yet.In this paper,we reviewed the domestic and international theoretical studies on the pathogenesis mechanism of chronic kidney disease-associated vascular calcification in recent years,summarized eight active ingredients of medicinal plants as well as four compound formulas for improving chronic kidney disease-associated vascular calcification,and explored the mechanism of action of herbal medicine,which will provide a new strategy for promoting the prevention and treatment of vascular calcification.展开更多
Calcitonin is a common medicine used in the treatment of osteoporosis,which could restrain the activity of osteoclasts,stop the loss of osteocalcin and reduce the transfer of osteocalcin.Calcitonin can also be used in...Calcitonin is a common medicine used in the treatment of osteoporosis,which could restrain the activity of osteoclasts,stop the loss of osteocalcin and reduce the transfer of osteocalcin.Calcitonin can also be used in the treatment of the pain-caused diseases which usually cause by hypercalcemia and others such like Paget's disease and bone tumors.As is approved by several clinic researches,calcitonin is powerful in adjusting the level of calcium,phosphorus and PTH during the treatment of renal osteodystrophy.In addition,it could improves the life quality of the patients who suffered from chronic kidney disease(CKD)and extending their life period.At present,several studies have shown us Calcitonin could be treated in renal osteodystrophy.However,the treatment experiences of Calcitonin are still lacking.Better understanding of the clinical evaluation for calcitonin in the treatment of renal osteodystrophy will hopefully help us to improve outcomes for these patients.展开更多
慢性肾脏病一矿物质和骨异常（chronic kidneydisease-mineral and bone disorder, CKD-MBD） 的防治是慢性肾脏病（chronic kidney disease, CKD）患者减少心血管疾病风险策略中的重要组成部分。早在20世纪30年代，中国学者首次提出了...慢性肾脏病一矿物质和骨异常（chronic kidneydisease-mineral and bone disorder, CKD-MBD） 的防治是慢性肾脏病（chronic kidney disease, CKD）患者减少心血管疾病风险策略中的重要组成部分。早在20世纪30年代，中国学者首次提出了肾性骨病（肾性骨营养不良）的概念。作为肾性骨病的延伸，CKD-MBD的定义诞生于2005年马德里举行的第一次CKD—MBD讨论会上。展开更多
文摘Vascular calcification is a crucial risk factor that affects the incidence and mortality of cardiovascular disease in chronic kidney disease patients.Modern medicine relies on calcium-phosphorus binding agents,calcium mimetics,active vitamin D,and hemodialysis to prevent and treat vascular calcification,however,their efficacy is unsatisfactory and adverse reactions often occur.Medical plant therapy can act as an integrative regulator in patients with chronic kidney disease-associated vascular calcification,which can significantly improve patients’symptoms,but its specific mechanism has not been fully elucidated yet.In this paper,we reviewed the domestic and international theoretical studies on the pathogenesis mechanism of chronic kidney disease-associated vascular calcification in recent years,summarized eight active ingredients of medicinal plants as well as four compound formulas for improving chronic kidney disease-associated vascular calcification,and explored the mechanism of action of herbal medicine,which will provide a new strategy for promoting the prevention and treatment of vascular calcification.
基金Guangzhou Development Zone entrepreneurship leading talent project(2017-L153)Guangdong University blood purification technology and Engineering Research Center(GCZX-A1104)+2 种基金Guangzhou entrepreneurial leader talent/LCY201215Guangdong Provincial Center for clinical engineering of blood purification(507204531040)Guangdong Obers Blood Purification A cademician Work station(2013B090400004)
文摘Calcitonin is a common medicine used in the treatment of osteoporosis,which could restrain the activity of osteoclasts,stop the loss of osteocalcin and reduce the transfer of osteocalcin.Calcitonin can also be used in the treatment of the pain-caused diseases which usually cause by hypercalcemia and others such like Paget's disease and bone tumors.As is approved by several clinic researches,calcitonin is powerful in adjusting the level of calcium,phosphorus and PTH during the treatment of renal osteodystrophy.In addition,it could improves the life quality of the patients who suffered from chronic kidney disease(CKD)and extending their life period.At present,several studies have shown us Calcitonin could be treated in renal osteodystrophy.However,the treatment experiences of Calcitonin are still lacking.Better understanding of the clinical evaluation for calcitonin in the treatment of renal osteodystrophy will hopefully help us to improve outcomes for these patients.
文摘慢性肾脏病一矿物质和骨异常（chronic kidneydisease-mineral and bone disorder, CKD-MBD） 的防治是慢性肾脏病（chronic kidney disease, CKD）患者减少心血管疾病风险策略中的重要组成部分。早在20世纪30年代，中国学者首次提出了肾性骨病（肾性骨营养不良）的概念。作为肾性骨病的延伸，CKD-MBD的定义诞生于2005年马德里举行的第一次CKD—MBD讨论会上。
